Loading clinical trials...
Loading clinical trials...
A Phase II Study of Ibrutinib as Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Conditions
Interventions
Echocardiography Test
Ibrutinib
Locations
1
United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Start Date
December 13, 2024
Primary Completion Date
June 30, 2027
Completion Date
June 30, 2027
Last Updated
December 26, 2025
NCT07025538
NCT01804686
NCT02474160
NCT07059884
NCT07220447
NCT06600659
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions